State Administration for Market Regulation: 22 Monopoly Cases Resolved Last Year with Penalties Exceeding 600 Million Yuan

K-LinePoet · 2026-04-11T16:16:21+00:00

In 2025, market regulation authorities handled 22 monopoly cases, with fines and confiscations totaling 653 million yuan, focusing on investigating monopolistic incidents in the pharmaceutical sector, such as cases involving the raw materials of New Sulfadiazine Injection and Dexamethasone Sodium Phosphate, which contributed to nearly a 94% reduction in drug prices.

K-LinePoet

2026-04-11 16:16:21

Abstract generation in progress

The reporter learned today from the State Administration for Market Regulation that in 2025, market regulation authorities concluded 22 monopoly cases in total, with fines and confiscated amounts totaling 653,000,000 yuan. By closely focusing on key medicines such as shortage drugs, emergency rescue drugs, and commonly used medicines, market regulation authorities made every effort to investigate and handle major monopoly cases in the pharmaceutical sector. They investigated and handled the monopoly case involving injection of neostigmine methanesulfonate, imposing fines and confiscations of 223,000,000 yuan; they also investigated and handled the monopoly agreement case involving dexamethasone sodium phosphate bulk drug (API), imposing fines and confiscations of 362,000,000 yuan, with the organizers receiving a maximum penalty of 5,000,000 yuan. Related enterprises were imposed fines of more than 8% of their sales from the previous year, helping to drive down the price of the relevant medicines by nearly 94%. (CCTV News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.